Work

Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

Year: 2022

Type: article

Abstract: Currently, there are no effective disease-modifying treatments for Alzheimer’s disease and related dementias (ADRD) (National Institute on Aging, 2021). In this context, considerable attention has been given to prevention […]

Source: NAM Perspectives

DOI: 10.31478/202205c

Authors: Zachary Marcum, Jordana Cohen, Eric Larson, Jeff Williamson, Adam Bress

Institutions: University of Washington, University of Pennsylvania, Kaiser Permanente Washington Health Research Institute, Wake Forest University Health Sciences, Wake Forest University, University of Utah

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute on Aging

Awards: Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens, Alzheimer's Disease Research Center

OpenAlex ID: W4229054431

FWCI: 0.815

Cites: 23

Cited by: 6

Related to: 10